Literature DB >> 26633263

Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells.

D Kata1, I Földesi2, L Z Feher3, L Hackler3, L G Puskas3, K Gulya4.   

Abstract

Microglial activation results in profound morphological, functional and gene expression changes that affect the pro- and anti-inflammatory mechanisms of these cells. Although statins have beneficial effects on inflammation, they have not been thoroughly investigated for their ability to affect microglial functions. Therefore the effects of rosuvastatin, one of the most commonly prescribed drugs in cardiovascular therapy, either alone or in combination with bacterial lipopolysaccharide (LPS), were profiled in pure microglial cultures derived from the forebrains of 18-day-old rat embryos. To reveal the effects of rosuvastatin on a number of pro- and anti-inflammatory mechanisms, we performed morphometric, functional and gene expression studies relating to cell adhesion and proliferation, phagocytosis, pro- and anti-inflammatory cytokine (IL-1β, tumor necrosis factor α (TNF-α) and IL-10, respectively) production, and the expression of various inflammation-related genes, including those related to the above morphological parameters and cellular functions. We found that microglia could be an important therapeutic target of rosuvastatin. In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-inflammatory cytokine production were unaffected. Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1β, TNF-α) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Finally, rosuvastatin beneficially and differentially affected the expression of a number of inflammation-related genes in LPS-challenged cells by inhibiting numerous pro-inflammatory and stimulating several anti-inflammatory genes. Since the microglia could elicit pro-inflammatory responses leading to neurodegeneration, it is important to attenuate such mechanisms and promote anti-inflammatory properties, and develop prophylactic therapies. By beneficially regulating both pro- and anti-inflammatory microglial functions, rosuvastatin may be considered as a prophylactic agent in the prevention of inflammation-related neurological disorders.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  anti-inflammation; gene expression; lipopolysaccharide; phagocytosis; pro-inflammation; rosuvastatin

Mesh:

Substances:

Year:  2015        PMID: 26633263     DOI: 10.1016/j.neuroscience.2015.11.053

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

Review 1.  Modulators of microglial activation and polarization after intracerebral haemorrhage.

Authors:  Xi Lan; Xiaoning Han; Qian Li; Qing-Wu Yang; Jian Wang
Journal:  Nat Rev Neurol       Date:  2017-05-19       Impact factor: 42.937

2.  Rosuvastatin Attenuates High-Salt and Cholesterol Diet Induced Neuroinflammation and Cognitive Impairment via Preventing Nuclear Factor KappaB Pathway.

Authors:  Ibraheem Husain; Mohd Akhtar; Divya Vohora; Malik Zainul Abdin; Mohammad Islamuddin; Mohd Jawaid Akhtar; Abul Kalam Najmi
Journal:  Neurochem Res       Date:  2017-04-18       Impact factor: 3.996

Review 3.  Drug repurposing-an emerging strategy in cancer therapeutics.

Authors:  Khadija Shahab Turabi; Ankita Deshmukh; Sayan Paul; Dayanand Swami; Shafina Siddiqui; Urwashi Kumar; Shreelekha Naikar; Shine Devarajan; Soumya Basu; Manash K Paul; Jyotirmoi Aich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-06-13       Impact factor: 3.195

4.  Therapeutic Delivery of Simvastatin Loaded in PLA-PEG Polymersomes Resulted in Amplification of Anti-inflammatory Effects in Activated Microglia.

Authors:  Dharani Manickavasagam; Kimberly Novak; Moses O Oyewumi
Journal:  AAPS J       Date:  2017-12-14       Impact factor: 4.009

5.  Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.

Authors:  A J McFarland; A K Davey; S Anoopkumar-Dukie
Journal:  Mediators Inflamm       Date:  2017-05-04       Impact factor: 4.711

Review 6.  The Polarization States of Microglia in TBI: A New Paradigm for Pharmacological Intervention.

Authors:  Hangzhe Xu; Zhijiang Wang; Jianru Li; Haijian Wu; Yucong Peng; Linfeng Fan; Jingyin Chen; Chi Gu; Feng Yan; Lin Wang; Gao Chen
Journal:  Neural Plast       Date:  2017-02-01       Impact factor: 3.599

7.  The Antineuroinflammatory Effect of Simvastatin on Lipopolysaccharide Activated Microglial Cells.

Authors:  Xinrui Zheng; Ye Liao; Jiu Wang; Shijie Hu; Gudepalya Renukaiah Rudramurthy; Mallappa Kumara Swamy; Komdur Channabasavaraju Rohit; Yangang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-07       Impact factor: 2.629

8.  The Topical Application of Rosuvastatin in Preventing Knee Intra-Articular Adhesion in Rats.

Authors:  Haixiao Wu; Alexey V Germanov; Galina L Goryaeva; Alexander N Yachmenev; Dmitriy I Gordienko; Victor V Kuzin; Alexander V Skoroglyadov
Journal:  Med Sci Monit       Date:  2016-04-26

9.  Real architecture For 3D Tissue (RAFT™) culture system improves viability and maintains insulin and glucagon production of mouse pancreatic islet cells.

Authors:  Gabor J Szebeni; Zsuzsanna Tancos; Liliana Z Feher; Robert Alfoldi; Julianna Kobolak; Andras Dinnyes; Laszlo G Puskas
Journal:  Cytotechnology       Date:  2017-02-08       Impact factor: 2.058

10.  Intraperitoneal administration of rosuvastatin prevents postoperative peritoneal adhesions by decreasing the release of tumor necrosis factor.

Authors:  Stefan Chiorescu; Octavian Aurel Andercou; Nicolae Ovidiu Grad; Ion Aurel Mironiuc
Journal:  Clujul Med       Date:  2018-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.